{ "ok": true, "cik": "885725", "ticker": "BSX", "name": "BOSTON SCIENTIFIC CORPORATION", "filings": [ { "form": "8-K", "filed": "2026-09-08", "items": [ "1.05 Material Cybersecurity Incidents" ], "url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000059/0000885725-26-000059-index.htm" }, { "form": "8-K", "filed": "2026-08-26", "items": [ "8.01 Other Events" ], "url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000056/0000885725-26-000056-index.htm" }, { "form": "10-Q", "filed": "2026-08-03", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/0000885725-26-000053-index.htm" }, { "form": "8-K", "filed": "2026-07-29", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/0000885725-26-000051-index.htm" }, { "form": "8-K", "filed": "2026-07-27", "items": [ "2.05 Costs Associated with Exit or Disposal Activities" ], "url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000049/0000885725-26-000049-index.htm" }, { "form": "8-K", "filed": "2026-05-18", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000042/0000885725-26-000042-index.htm" } ], "events12m": 18, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000885725.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=885725" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up BOSTON SCIENTIFIC CORPORATION ($BSX). Last filing: 8-K (1.05 Material Cybersecurity Incidents), 2026-09-08. 18 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 20074000000, "revenueGrowth1y": 0.1986624470054339, "revenueGrowthPerYear": 0.13993813039925906, "yearsOfData": 5, "operatingMargin": 0.17998405898176745, "operatingMarginPrior": 0.1554308234310623, "netMargin": 0.14406695227657668, "operatingCashFlow": 4534000000, "capitalSpending": 876000000, "freeCashFlow": 3658000000, "researchAndDevelopment": 2052000000, "researchShareOfRevenue": 0.1022217794161602, "cash": 1965000000, "longTermDebt": 11137000000, "longTermDebtChange": 0.24185994647636044, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 11888000000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 12682000000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 14240000000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 16747000000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 20074000000 } ], "totalEquity": 24233000000, "totalAssets": 43673000000, "equityRatio": 0.5548737206054084, "returnOnEquity": 0.11934139396690463, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": { "low": 18754836054.46328, "high": 26912620259.327248, "baseline": 23728284481.86144, "n": 1471, "band": "b10" }, "ifPaceHeld": { "low": 18754836054.46328, "high": 26912620259.327248 } }, "edgarette": "🔖 Exposure: revenue $20.1B (FY2025), total debt $11.1B. Experience: revenue up 19.9% on the year, up 14.0% a year over 4 years; operating margin 18.0%, up from 15.5%. Soundness: equity 55.5% of assets, return on equity 11.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $18.8B and $26.9B next year (method v3, set from 1,471 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 18.0% against a 1.2% median; growth 19.9% against 11.6%.", "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "summary": "Boston Scientific (BSX) grew revenue 19.9% in FY2025 to $20.1 billion, operating margin 18.0% against a 1.2% median for surgical & medical instruments & apparatus, equity 55.5% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
BOSTON SCIENTIFIC CORPORATION against its own record and its peers
Operating marginPeer median 1.2%18.0%Revenue, on the yearPeer median 11.6%19.9%Equity of assetsPeer median 52.9%55.5%Return on equityPeer median -2.3%11.9%Gold tick: the median of 55–59 peers with $50M+ revenue in surgical & medical instruments & apparatus
", "chartHorizon": null, "backtest": { "tests": 15, "hits": 14, "rate": 0.9333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:07:07.096Z", "hash": "18d503191fb8eace", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Boston Scientific (BSX) grew revenue 19.9% in FY2025 to $20.1 billion, operating margin 18.0% against a 1.2% median for surgical & medical instruments & apparatus, equity 55.5% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 20074000000, "totalDebt": 11137000000, "cash": 1965000000 }, "experience": { "revenueGrowth1y": 0.1986624470054339, "revenueGrowthPerYear": 0.13993813039925906, "operatingMargin": 0.17998405898176745, "operatingMarginPrior": 0.1554308234310623, "netMargin": 0.14406695227657668, "freeCashFlow": 3658000000 }, "soundness": { "equityRatio": 0.5548737206054084, "returnOnEquity": 0.11934139396690463, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 3841, "sicDescription": "Surgical & Medical Instruments & Apparatus", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "3841", "growth": [ 0.1161, 60 ], "opMargin": [ 0.0124, 60 ], "equityRatio": [ 0.5291, 59 ], "returnOnEquity": [ -0.0233, 55 ], "payoutRatio": [ 0.3812, 8 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "range": { "low": 18754836054.46328, "high": 26912620259.327248, "baseline": 23728284481.86144, "coverage": 0.8, "method": "v3", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); range = 10th to 90th percentile of how SEC company-years of the same size band actually turned out", "calibratedOn": { "companyYears": 1471, "sizeBand": "b10" }, "kind": "a calibrated range, not a forecast; no view on the share price", "track": { "backtest": { "tests": 15, "hits": 14, "rate": 0.9333333333333333, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "registry": { "logged": "2026-09-20T14:07:07.096Z", "hash": "18d503191fb8eace", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0000885725.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=885725" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }